>亚太人工智能 (AI) 药物研发市场，按应用（新型候选药物、药物优化和再利用临床前测试和批准、药物监测、寻找新疾病相关靶点和途径、了解疾病机制、汇总和综合信息、假设的形成和验证、从头药物设计、寻找旧药的药物靶点等）、技术（机器学习、深度学习、自然语言处理等）、药物类型（小分子和大分子）、产品（软件和服务）、适应症（免疫肿瘤学、神经退行性疾病、心血管疾病、代谢疾病等）、最终用途（合同研究组织 (CRO)、制药和生物技术公司、研究中心和学术机构等）行业趋势和预测到 2029 年。
亚太地区人工智能药物研发市场分析与洞察
人工智能 (AI) 有望成为医疗保健行业的一项利润丰厚的技术。人工智能的实施减少了药物制造过程中的研发差距，并有助于药物的有针对性制造。因此，生物制药公司正在转向人工智能来提高其市场份额。用于药物发现的人工智能是一种使用机器模拟人类智能来解决药物开发过程中复杂挑战的技术。
在临床试验过程中采用人工智能解决方案可消除可能的障碍，缩短临床试验周期，并提高临床试验过程的生产率和准确性。药物发现人工智能技术的进步和药物发现过程总时间的减少是预测期内推动市场增长的其他因素。然而，低质量和不一致的可用数据将阻碍市场增长。此外，与技术相关的高成本和技术限制将抑制市场增长。
Data Bridge Market Research 分析称，亚太地区药物研发人工智能 (AI) 市场的价值预计将在 2029 年达到 34.2404 亿美元，预测期内的复合年增长率为 50.9%。由于技术进步的快速发展，AI 在药物研发市场中的商业化应用，软件占据了市场中最大的技术领域。本市场报告还深入介绍了定价分析、专利分析和技术进步。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020 (可定制为 2019-2014) |
|
定量单位 |
收入（百万美元），定价（美元） |
|
涵盖的领域 |
按应用（新型候选药物、药物优化和再利用临床前测试和批准、药物监测、寻找新的疾病相关靶点和途径、了解疾病机制、汇总和综合信息、假设的形成和验证、从头药物设计、寻找旧药的药物靶点等）、技术（机器学习、深度学习、自然语言处理等）、药物类型（小分子和大分子）、产品（软件和服务）、适应症（免疫肿瘤学、神经退行性疾病、心血管疾病、代谢疾病等）、最终用途（合同研究组织 (CRO)、制药和生物技术公司、研究中心和学术机构等） |
|
覆盖国家 |
中国、日本、印度、韩国、新加坡、泰国、马来西亚、澳大利亚和新西兰、菲律宾、印度尼西亚、亚太地区其他地区 |
|
涵盖的市场参与者 |
市场上的一些主要参与者包括 NVIDIA Corporation、IBM Corp.、Atomwise Inc.、Microsoft、Benevolent AI、Aria Pharmaceuticals, Inc.、DEEP GENOMICS、Exscientia、Cloud、Insilico Medicine、Cyclica、NuMedii, Inc.、Envisagenics、Owkin Inc.、BERG LLC、Schrödinger, Inc.、XtalPi Inc. 和 BIOAGE Inc. 等 |
亚太地区药物研发人工智能 (AI) 市场定义
过去几年，随着多家公司和大型研究实验室致力于完善这些技术以用于临床，人工智能引起了医疗技术从业者的关注和关注。人工智能（也称为深度学习 (DL)、机器学习 (ML) 或人工神经网络 (ANN)）如何协助临床医生的首批商业化演示现已面世。这些系统可能导致临床医生工作流程发生范式转变，提高工作效率，同时提高治疗和患者吞吐量。用于药物发现的人工智能是一种使用机器模拟人类智能来解决药物开发过程中复杂挑战的技术。在临床试验过程中采用人工智能解决方案可以消除可能的障碍，缩短临床试验周期，并提高临床试验过程的生产力和准确性。因此，在药物发现过程中采用这些先进的人工智能解决方案在生命科学行业利益相关者中越来越受欢迎。在制药领域，它有助于发现新化合物、识别治疗靶点和开发定制药物。用于药物研发的人工智能平台被证明是一种可行的选择，可以深入了解治疗各种慢性疾病并尽量减轻其严重程度的药物研发过程。
亚太地区人工智能（AI）药物研发市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
- 慢性病发病率上升推动药物研发对人工智能的需求
慢性病的发病率在全球范围内迅速上升。根据美国疾病控制和预防中心（CDC）的数据，美国每10个成年人中就有6个患有慢性病。此外，CDC还强调，心脏病和糖尿病等慢性病是美国死亡的主要原因。这些数据表明，慢性病的发病率正在不断上升，有必要降低这些疾病造成的死亡率。
用于药物研发的人工智能平台已被证明是一种可行的选择，可以深入了解药物研发，以治疗和尽量减轻各种慢性疾病的严重程度。因此，这些因素有望在预测期内成为市场增长的驱动力。
- 战略合作、伙伴关系和产品发布
人工智能有潜力改变药物发现，可以快速加快研发时间，降低药物开发成本并加快药物开发速度，提高药物获批的概率。人工智能还可以提高药物再利用研究的有效性。
跨行业联盟和合作的增加推动了市场的发展。人工智能在药物发现和开发中的重要性日益提高，包括药物研究领域的人工智能技术在内的研发活动资金激增，预计将推动全球市场的增长。因此，跨行业合作和伙伴关系的增加正在推动市场的发展。
克制
- 与技术和技术限制相关的高成本
当前的医疗保健行业面临着许多复杂的挑战，例如药品和治疗费用的增加，社会需要在这一领域做出具体的重大改变。人工智能的整个成功取决于大量数据的可用性，因为这些数据将用于对系统进行的后续训练。访问来自不同数据库提供商的数据可能会给公司带来额外成本。临床试验旨在确定药物产品对特定疾病状况的安全性和有效性，需要六到七年的时间以及大量的资金投入。然而，参加这些试验的十分之一的分子只能成功获得批准，这对行业来说是一个巨大的损失。这些失败可能是由于患者选择不当、技术要求不足和基础设施薄弱造成的。因此，技术成本的增加正在成为市场增长的制约因素。
机会
-
研发投资增加
研发活动的增加和基于云的服务和应用程序的日益采用将为市场增长提供有利的机会。
经过长期的低迷期后，生物制药领域的人工智能行业继续增长。这反映在 2021 年与前几年相比，制药公司和人工智能公司之间的投资持续流动和合作数量的增加。生物制药行业的增长在很大程度上受到领先制药公司积极参与人工智能相关投资的影响。生物制药领域人工智能的科学出版物数量以及制药公司和人工智能专业知识供应商之间的研究合作正在迅速增加，然而，一些制药公司仍然对人工智能应用持批评态度。制药和医疗保健行业的机器学习和人工智能应用导致了医疗保健领域数据驱动药物发现这一新跨学科领域的形成。因此，研发活动投资的增加为市场增长提供了机会。
挑战
- 缺乏熟练的专业人员
预计熟练专业人员的短缺将阻碍市场增长。员工必须重新培训或学习新技能，才能在复杂的人工智能机器上高效工作，从而获得药物的预期效果。这一挑战阻碍了制药行业全面采用人工智能，包括缺乏熟练的人员来操作基于人工智能的平台、小型组织的预算有限、担心取代人类会导致失业、对人工智能生成的数据的怀疑以及黑箱现象（即人工智能平台如何得出结论）。技能短缺是通过人工智能发现药物的主要障碍，阻碍了公司采用基于人工智能的机器进行药物发现。
由于技能需求过高，留住和管理技能型专业人员已成为一项挑战。此外，技术进步是导致对技能型专业人员需求增加的另一个方面。迫切需要对基于人工智能技术的专业人员进行教育。缺乏训练有素且经验丰富的专业人员以及持续存在的技能差距限制了就业前景和获得优质工作的机会。因此，显然，拥有足够技能的专业人员的可用性对市场增长构成了挑战。
后新冠疫情对亚太地区药物研发人工智能市场的影响
COVID-19 疫情对药物研发行业 AI 的扩张产生了有益影响，因为各种组织广泛使用 AI 来识别和筛选用于治疗 COVID-19 的现有药物。AI 可用于检测预防 SARS-CoV、HIV、SARS-CoV-2、流感病毒等的活性化学物质。在疫情期间，世界各地的经济体都依赖于基于 AI 的药物研发，而不是传统的疫苗检测流程，后者需要数年时间才能开发出来，而且成本同样高昂，这促进了市场的增长。
制造商正在制定各种战略决策，以在新冠疫情后实现复苏。参与者正在进行多项研发活动，以改进无线麦克风所涉及的技术。借助此，这些公司将向市场推出先进而准确的 AI 软件。
最新动态
- 2022 年 3 月，NVIDIA 公司推出了 Clara Holoscan MGX，用于开发和部署实时 AI 应用程序。Clara Holoscan MGX 扩展了 Clara Holoscan 平台，提供一体化、医疗级参考架构以及长期软件支持，以加速医疗器械行业的创新。这将有助于该公司在医疗领域的手术、诊断和药物研发方面获得更好的 AI 性能。
- 2022 年 5 月，领先的临床阶段 AI 药物研发公司 Benevolent AI 宣布，阿斯利康已为其药物开发组合选择了特发性肺纤维化 (IPF) 的另一个新靶点，从而向 Benevolent AI 支付了一笔里程碑式付款。这是合作中利用 Benevolent 平台在特发性肺纤维化和慢性肾病两个疾病领域确定的第三个新靶点，随后由阿斯利康验证和选择进入组合。这是在最近与阿斯利康扩大合作的基础上，于 2022 年 1 月签署了两个新的疾病领域，即系统性红斑狼疮和心力衰竭的协议。这有助于该公司加强合作。
亚太地区人工智能（AI）药物研发市场范围
亚太地区药物研发人工智能 (AI) 市场细分为应用、技术、药物类型、产品、适应症和最终用途。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
应用
- 新型候选药物
- 药物优化和再利用临床前测试和审批
- 药物监测
- 寻找新的疾病相关靶点和途径
- 了解疾病机制
- 汇总和综合信息
- 假设的形成与验证
- 从头药物设计
- 寻找老药的药物靶点
- 其他的
根据应用，市场细分为新型候选药物、药物优化和再利用临床前测试和批准、药物监测、寻找与新疾病相关的靶点和途径、了解疾病机制、汇总和综合信息、形成和验证假设、从头药物设计、寻找旧药的药物靶点等。
技术
- 机器学习 (ML)
- 深度学习（DL）
- 自然语言处理 (NLP)
- 其他的
根据技术，市场细分为机器学习（ML）、深度学习（DL）、自然语言处理（NLP）等。
药物类型
- 小分子
- 大分子
根据药物类型，市场分为小分子和大分子。
提供
- 软件
- 服务
根据产品类型，市场分为软件和服务。
适应症
- 免疫肿瘤学
- 神经退行性疾病
- 心血管疾病
- 代谢疾病
- 其他的
根据适应症，市场分为免疫肿瘤学、神经退行性疾病、心血管疾病、代谢疾病等。
最终用途
- 制药及生物技术公司
- 合同研究组织 (CRO)
- 研究中心和学术机构
- 其他的
根据最终用途，市场分为制药和生物技术公司、合同研究组织 (CRO)、研究中心和学术机构等。
亚太地区人工智能（AI）药物研发市场区域分析/洞察
对亚太地区药物研发中的人工智能 (AI) 市场进行了分析，并按应用、技术、药物类型、产品、适应症和最终用途提供了市场规模信息。
本市场报告涵盖的国家包括中国、日本、印度、韩国、新加坡、泰国、马来西亚、澳大利亚和新西兰、菲律宾、印度尼西亚以及亚太地区其他地区。
- 2022 年，亚太地区将成为第三大主要地区，因为随着患者人数增加和人们意识的提高，对传染病诊断试剂盒的需求也随之增加。由于药物研发人工智能技术的进步，中国预计将实现增长。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了亚太品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战，以及销售渠道的影响。
亚太地区人工智能药物研发市场竞争格局及份额分析
亚太地区药物发现人工智能 (AI) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对亚太地区药物发现人工智能 (AI) 市场的关注有关。
市场上的一些主要参与者包括 NVIDIA Corporation、IBM Corp.、Atomwise Inc.、Microsoft、Benevolent AI、Aria Pharmaceuticals, Inc.、DEEP GENOMICS、Exscientia、Cloud、Insilico Medicine、Cyclica、NuMedii, Inc.、Envisagenics、Owkin Inc.、BERG LLC、Schrödinger, Inc.、XtalPi Inc. 和 BIOAGE Inc. 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORETSR’S FIVE FORCES
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 THE RISE IN INCIDENCE OF CHRONIC DISEASES PROPELS NEED FOR ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY
5.1.2 STRATEGIC COLLABORATIONS, PARTNERSHIPS, AND PRODUCTS LAUNCH
5.1.3 REDUCTION IN TOTAL TIME INVOLVED IN DRUG DISCOVERY PROCESS
5.1.4 ADVANCEMENT OF ARTIFICIAL INTELLIGENCE IN THE HEALTHCARE INDUSTRY
5.2 RESTRAINTS
5.2.1 HIGH COST ASSOCIATED WITH TECHNOLOGY AND TECHNICAL LIMITATIONS
5.2.2 DISADVANTAGES AND RISKS ASSOCIATED WITH AI IN DRUG DISCOVERY
5.2.3 LACK OF AVAILABLE QUALITY DATA
5.3 OPPORTUNITIES
5.3.1 RISE IN THE INVESTMENTS FOR R&D
5.3.2 RISING HEALTHCARE INFRASTRUCTURE
5.3.3 DEVELOPMENT OF NOVEL TOOLS
5.4 CHALLENGES
5.4.1 THE ASIA PACIFIC SHORTAGE OF AI TALENT
5.4.2 ETHICAL, LEGAL, AND REGULATORY ISSUES FOR AI ADOPTION IN THE PHARMACEUTICAL SCIENCES
6 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING
6.1 OVERVIEW
6.2 SOFTWARE
6.2.1 INTEGRATED
6.2.2 STANDALONE
6.3 SERVICES
7 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY
7.1 OVERVIEW
7.2 MACHINE LEARNING (ML)
7.2.1 SUPERVISED LEARNING
7.2.2 UNSUPERVISED LEARNING
7.2.3 REINFORCEMENT LEARNING
7.3 DEEP LEARNING
7.4 NATURAL LANGUAGE PROCESSING (NLP)
7.5 OTHERS
8 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET , BY DRUG TYPE
8.1 OVERVIEW
8.2 SMALL MOLECULE
8.3 LARGE MOLECULE
9 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 NOVEL DRUG CANDIDATES
9.2.1 PREDICT BIOACTIVITY OF SMALL MOLECULE
9.2.2 IDENTIFY BIOLOGICS TARGET
9.2.3 OTHERS
9.3 DRUG OPTIMISATION AND RE-PURPOSING PRE-CLINICAL TESTING AND APPROVAL
9.4 DRUG MONITORING
9.5 AGGREGATING AND SYNTHESIZING INFORMATION
9.6 DE NOVO DRUG DESIGN
9.7 FINDING DRUG TARGETS OF AN OLD DRUG
9.8 FORMATION & QUALIFICATION OF HYPOTHESES
9.9 UNDERSTANDING DISEASE MECHANISMS
9.1 FINDING NEW DISEASE-ASSOCIATED TARGETS AND PATHWAYS
9.11 OTHERS
10 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION
10.1 OVERVIEW
10.2 IMMUNE-ONCOLOGY
10.2.1 BREAST CANCER
10.2.2 LUNG CANCER
10.2.3 COLORECTAL CANCER
10.2.4 PROSTATE CANCER
10.2.5 PANCREATIC CANCER
10.2.6 BRAIN CANCER
10.2.7 LEUKEMIA
10.2.8 OTHERS
10.3 NEURODEGENERATIVE DISEASES
10.4 CARDIOVASCULAR DISEASES
10.5 METABOLIC DISEASES
10.6 OTHERS
11 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET , BY END USE
11.1 OVERVIEW
11.2 CONTRACT RESEARCH ORGANIZATIONS
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.4 RESEARCH CENTERS AND ACADEMIC INSTITUTES
11.5 OTHERS
12 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION
12.1 ASIA-PACIFIC
12.1.1 CHINA
12.1.2 JAPAN
12.1.3 SOUTH KOREA
12.1.4 INDIA
12.1.5 AUSTRALIA & NEW ZEALAND
12.1.6 SINGAPORE
12.1.7 THAILAND
12.1.8 MALAYSIA
12.1.9 INDONESIA
12.1.10 PHILIPPINES
12.1.11 REST OF ASIA-PACIFIC
13 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 NVIDIA CORPORATION
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 MICROSOFT
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 IBM CORP
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 SCHRÖDINGER, INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 BERG LLC
15.5.1 COMPANY SNAPSHOT
15.5.2 COMPANY SHARE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENTS
15.6 ARDIGEN
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENTS
15.7 EXSCIENTIA
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENTS
15.8 ARIA PHARMACEUTICALS, INC.
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 ATOMWISE INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENTS
15.1 BENEVOLENT AI
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENTS
15.11 BIOAGE INC.,
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 CLOUD
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 CYCLICA
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENTS
15.14 DEEP GENOMICS
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 ENVISAGENICS
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENTS
15.16 INSILICO MEDICINE
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENTS
15.17 NUMEDII, INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 OWKIN INC.
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 XTALPI INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 2 ASIA PACIFIC SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC SERVICES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC DEEP LEARNING IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC NATURAL LANGUAGE PROCESSING (NLP) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC OTHERS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC SMALL MOLECULE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC LARGE MOLECULE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC DRUG OPTIMISATION AND RE-PURPOSING PRE-CLINICAL TESTING AND APPROVAL IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC DRUG MONITORING IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC AGGREGATING AND SYNTHESIZING INFORMATION IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC DE NOVO DRUG DESIGN IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC FINDING DRUG TARGETS OF AN OLD DRUG IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC FORMATION & QUALIFICATION OF HYPOTHESES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC UNDERSTANDING DISEASE MECHANISMS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC FINDING NEW DISEASE-ASSOCIATED TARGETS AND PATHWAYS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC OTHERS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC NEURODEGENERATIVE DISEASES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC CARDIOVASCULAR DISEASES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC METABOLIC DISEASES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC OTHERS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 GLOB ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 34 ASIA PACIFIC CONTRACT RESEARCH ORGANIZATIONS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 ASIA PACIFIC PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 ASIA PACIFIC RESEARCH CENTRES AND ACADEMIC INSTITUTES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 ASIA PACIFIC OTHERS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 49 CHINA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 50 CHINA SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 CHINA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 52 CHINA MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 53 CHINA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 54 CHINA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 55 CHINA NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 CHINA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 57 CHINA IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 58 CHINA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 59 JAPAN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 60 JAPAN SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 JAPAN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 62 JAPAN MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 63 JAPAN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 64 JAPAN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 65 JAPAN NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 66 JAPAN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 67 JAPAN IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 68 JAPAN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 69 SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 70 SOUTH KOREA SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 72 SOUTH KOREA MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 73 SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 74 SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 75 SOUTH KOREA NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 76 SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 77 SOUTH KOREA IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 78 SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 79 INDIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 80 INDIA SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 INDIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 82 INDIA MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 83 INDIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 84 INDIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 85 INDIA NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 86 INDIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 87 INDIA IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 88 INDIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 89 AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 90 AUSTRALIA & NEW ZEALAND SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 92 AUSTRALIA & NEW ZEALAND MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 93 AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 94 AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 95 AUSTRALIA & NEW ZEALAND NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 96 AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 97 AUSTRALIA & NEW ZEALAND IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 98 AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 99 SINGAPORE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 100 SINGAPORE SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 SINGAPORE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 102 SINGAPORE MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 103 SINGAPORE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 104 SINGAPORE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 105 SINGAPORE NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 106 SINGAPORE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 107 SINGAPORE IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 108 SINGAPORE AARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 109 THAILAND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 110 THAILAND SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 THAILAND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 112 THAILAND MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 113 THAILAND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 114 THAILAND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 115 THAILAND NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 116 THAILAND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 117 THAILAND IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 118 THAILAND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 119 MALAYSIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 120 MALAYSIA SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 MALAYSIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 122 MALAYSIA MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 123 MALAYSIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 124 MALAYSIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 125 MALAYSIA NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 126 MALAYSIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 127 MALAYSIA IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 128 MALAYSIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 129 INDONESIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 130 INDONESIA SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 INDONESIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 132 INDONESIA MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 133 INDONESIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 134 INDONESIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 135 INDONESIA NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 136 INDONESIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 137 INDONESIA IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 138 INDONESIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 139 PHILIPPINES ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
TABLE 140 PHILIPPINES SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 141 PHILIPPINES ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 142 PHILIPPINES MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 143 PHILIPPINES ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 144 PHILIPPINES ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 145 PHILIPPINES NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 146 PHILIPPINES ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 147 PHILIPPINES IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 148 PHILIPPINES ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)
TABLE 149 REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: SEGMENTATION
FIGURE 11 THE GROWING NEED TO CURB DRUG DISCOVERY COSTS AND REDUCE TIME INVOLVED IN THE DRUG DEVELOPMENT PROCESS, THE RISING ADOPTION OF CLOUD-BASED APPLICATIONS AND SERVICES, AND THE IMPENDING PATENT EXPIRY OF BLOCKBUSTER DRUGS ARE EXPECTED TO DRIVE THE GROWTH OF THE ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 SOFTWARE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET IN 2022 AND 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET
FIGURE 14 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY OFFERING, 2021
FIGURE 15 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY OFFERING, 2022-2029 (USD MILLION)
FIGURE 16 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY OFFERING, CAGR (2022-2029)
FIGURE 17 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY OFFERING, LIFELINE CURVE
FIGURE 18 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY TECHNOLOGY, 2021
FIGURE 19 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY TECHNOLOGY, 2022-2029 (USD MILLION)
FIGURE 20 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 21 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET : BY DRUG TYPE, 2021
FIGURE 23 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET : BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 24 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET : BY DRUG TYPE, CAGR (2022-2029)
FIGURE 25 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET : BY DRUG TYPE, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY APPLICATION, 2021
FIGURE 27 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 28 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 29 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 30 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY INDICATION, 2021
FIGURE 31 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY INDICATION, 2020-2029 (USD MILLION)
FIGURE 32 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY INDICATION, CAGR (2022-2029)
FIGURE 33 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 34 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY END USE, 2021
FIGURE 35 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY END USE, 2022-2029 (USD MILLION)
FIGURE 36 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET : BY END USE, CAGR (2022-2029)
FIGURE 37 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET : BY END USE, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: SNAPSHOT (2021)
FIGURE 39 ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY COUNTRY (2021)
FIGURE 40 ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY OFFERING (2022-2029)
FIGURE 43 ASIA PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
